Prevalent new user designs: A literature review of current implementation practice

Author:

Tazare John1ORCID,Gibbons Daniel C.2,Bokern Marleen1,Williamson Elizabeth J.13,Gillespie Iain A.2,Cunnington Marianne4,Logie John2,Douglas Ian J.13

Affiliation:

1. Faculty of Epidemiology and Population Health London School of Hygiene and Tropical Medicine London UK

2. GSK London UK

3. Health Data Research United Kingdom (HDR‐UK) London UK

4. Analysis Group Inc. London UK

Abstract

AbstractPurposePrevalent new user (PNU) designs extend the active comparator new user design by allowing for the inclusion of initiators of the study drug who were previously on a comparator treatment. We performed a literature review summarising current practice.MethodsPubMed was searched for studies applying the PNU design since its proposal in 2017. The review focused on three components. First, we extracted information on the overall study design, including the database used. We summarised information on implementation of the PNU design, including key decisions relating to exposure set definition and estimation of time‐conditional propensity scores. Finally, we reviewed the analysis strategy of the matched cohort.ResultsNineteen studies met the criteria for inclusion. Most studies (73%) implemented the PNU design in electronic health record or registry databases, with the remaining using insurance claims databases. Of 15 studies including a class of prevalent users, 40% deviated from the original exposure set definition proposals in favour of a more complex definition. Four studies did not include prevalent new users but used other aspects of the PNU framework. Several studies lacked details on exposure set definition (n = 2), time‐conditional propensity score model (n = 2) or integration of complex analytical techniques, such as the high‐dimensional propensity score algorithm (n = 3).ConclusionPNU designs have been applied in a range of therapeutic and disease areas. However, to encourage more widespread use of this design and help shape best practice, there is a need for improved accessibility, specifically through the provision of analytical code alongside guidance to support implementation and transparent reporting.

Funder

GlaxoSmithKline

Publisher

Wiley

Subject

Pharmacology (medical),Epidemiology

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3